Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:

	As of March 31, 2020				Fair Value Measurements
	Carrying		Fair		As of March 31, 2020
	Amount		Value		Level 1		Level 2		Level 3
Liabilities:						(unaudited)
Contingent consideration:
Asuragen ⁽¹⁾	$	2,866	$	2,866	$	-	$	-	$	2,866
Other long-term liabilities:
Warrant liability ⁽²⁾		55		55		-		-		55
	$	2,921	$	2,921	$	-	$	-	$	2,921

	As of December 31, 2019				Fair Value Measurements
	Carrying		Fair		As of December 31, 2019
	Amount		Value		Level 1		Level 2		Level 3

Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	2,893	$	2,893	$	-	$	-	$	2,893
Other long-term liabilities:
Warrant liability ⁽²⁾		82		82		-		-		82
	$	2,975	$	2,975	$	-	$	-	$	2,975

⁽¹⁾⁽²⁾See Note 9, Accrued Expenses and Long-Term Liabilities

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

A roll forward of the carrying value of the Contingent Consideration Liability and the Underwriters’ Warrants to March 31, 2020 is as follows:

								Cancellation		Adjustment
								of Obligation/		to Fair Value/
	December 31, 2019		Payments			Accretion		Conversions Exercises		Mark to Market			March 31, 2020
	(unaudited)
Asuragen	$	2,893	$	(136	)	$	109	$	-	$	-		$	2,866

Underwriters Warrants		82		-			-		-		(27	)		55
	$	2,975	$	(136	)	$	109	$	-	$	(27	)	$	2,921